105 related articles for article (PubMed ID: 3144698)
1. Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
Wang JY
Oncogene Res; 1988; 3(3):293-8. PubMed ID: 3144698
[TBL] [Abstract][Full Text] [Related]
2. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential.
Franz WM; Berger P; Wang JY
EMBO J; 1989 Jan; 8(1):137-47. PubMed ID: 2496972
[TBL] [Abstract][Full Text] [Related]
3. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
Mysliwiec T; Perego R; Kruh GD
Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
[TBL] [Abstract][Full Text] [Related]
4. Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Shore SK; Bogart SL; Reddy EP
Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6502-6. PubMed ID: 2168550
[TBL] [Abstract][Full Text] [Related]
5. A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.
Okuda K; D'Andrea A; Etten RA; Griffin JD
J Clin Invest; 1997 Oct; 100(7):1708-15. PubMed ID: 9312168
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Lugo TG; Pendergast AM; Muller AJ; Witte ON
Science; 1990 Mar; 247(4946):1079-82. PubMed ID: 2408149
[TBL] [Abstract][Full Text] [Related]
8. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
9. Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Kamps MP; Sefton BM
Oncogene Res; 1988 Sep; 3(2):105-15. PubMed ID: 2465525
[TBL] [Abstract][Full Text] [Related]
10. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
12. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Jackson PK; Paskind M; Baltimore D
Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
14. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
[TBL] [Abstract][Full Text] [Related]
15. Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.
Yi CR; Rosenberg N
J Virol; 2007 Sep; 81(17):9461-8. PubMed ID: 17596313
[TBL] [Abstract][Full Text] [Related]
16. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
Juang JL; Hoffmann FM
Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
[TBL] [Abstract][Full Text] [Related]
17. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
[TBL] [Abstract][Full Text] [Related]
18. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
19. The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
Lionberger JM; Smithgall TE
Cancer Res; 2000 Feb; 60(4):1097-103. PubMed ID: 10706130
[TBL] [Abstract][Full Text] [Related]
20. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
